Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

NNC0114-0006

Generic Name: NNC0114-0006

Drug Type: Biotech

Unique Ingredient Identifier: L1SQ55DADE

Overview

NNC0114-0006 is an anti-interleukin 21 monoclonal antibody

Background

NNC0114-0006 is an anti-interleukin 21 monoclonal antibody

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Phase 2

Completed

Posted: 2015/05/13

Sponsor:Novo Nordisk A/S

ID:NCT02443155

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Phase 2

Completed

Posted: 2012/12/17

Sponsor:Novo Nordisk A/S

ID:NCT01751152

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Phase 1

Terminated

Posted: 2012/09/20

Sponsor:Novo Nordisk A/S

ID:NCT01689025

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Posted: 2012/07/23

Sponsor:Novo Nordisk A/S

ID:NCT01647451

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Posted: 2012/03/28

Sponsor:Novo Nordisk A/S

ID:NCT01565408

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy